



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

complete if Known

Application Number	09/781,980
Filing Date	14 February 2001
First Named Inventor	EISENHUT
Art Unit	1635
Examiner Name	Schultz
Attorney Docket Number	41443

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Country Code-Number- Kind Code (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publishers, city and/or country where published	T
JDS	✓	NAGY, Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin, Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 1794-1799, February 1998.	
	✓	KRENNING, Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy, Annals of Oncology (suppl. 2): S23-S29, 1999, Kluwer Academic Publishers.	
		HO, Antisense Oligonucleotides as Therapeutics for Malignant Diseases, Seminars in Oncology, Vol. 24, No. 2 (April, 1997: pp 187-202.	
		MIER, Preparation and Evaluation of Tumor-Targeting Peptide-Oligonucleotide Conjugates, Bioconjugate Chem. 2000, 11, 855-860.	

Examiner
SignatureDate
Considered

4-18-03